Navigation Links
Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
Date:2/17/2011

VELOUR studies are anticipated in the first half of 2011.  Based on projected event rates, an interim analysis of the VENICE study is expected to be conducted by an Independent Data Monitoring Committee in mid-2011, with final results anticipated in 2012.  

In addition, a randomized Phase 2 study (AFFIRM) is evaluating aflibercept as a 1st-line treatment for metastatic colorectal cancer in combination with FOLFOX (folinic acid [leucovorin], 5-fluorouracil, and oxaliplatin).  The AFFIRM study is fully enrolled, and initial data are anticipated in the second half of 2011.

Monoclonal AntibodiesSince 2007, Regeneron and sanofi-aventis have collaborated on the discovery, development, and commercialization of fully human monoclonal antibodies generated by Regeneron using its VelocImmune® technology.  During the fourth quarter of 2009, Regeneron and sanofi-aventis expanded and extended their collaboration with the objective to advance an average of four to five antibodies into clinical development each year between 2010 and 2017.  The following eight antibody candidates are currently in clinical development under the collaboration:

REGN727, an antibody to Proprotein Convertase Substilisin/Kexin type 9 (PCSK9), a novel target for LDL cholesterol ("bad cholesterol") reduction, has been evaluated in Phase 1 studies using both intravenous and subcutaneous routes of administration.  REGN727 is being studied as a single agent and in combination with statin therapy.  Phase 2 studies have been initiated in patients with hypercholesterolemia.  

REGN88, an antibody to the interleukin-6 receptor (IL-6R), is in a Phase 2/3 study in rheumatoid arthritis and a Phase 2 study in ankylosing spondylitis, a form of arthritis that primarily affects the spine.  Both studies are enrolling patients, and initial Phase 2 results are expected in 2011.

REGN421, an antibody to
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... 2014 - New Solution That ... JIN Co., Ltd. will launch JINS MEME "ACADEMIC ... 500,000 yen or $5,000 (without tax /including two pairs of ... is a dedicated solution of "JINS MEME" to academic researchers, ... data* generated by electrooculography and six-axis sensors without API. (*Physiological ...
(Date:11/26/2014)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; ... Products®," today announced the closing of Perrigo,s previously announced ... ordinary shares at a public offering price of $152.00 ... to purchase up to an additional 888,157 ordinary shares ... as representatives of the several underwriters. ...
(Date:11/26/2014)... 26, 2014   Regulus Therapeutics Inc . (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, today ... and CEO of Regulus, will present a company overview ... Conference at the New York Palace Hotel on Wednesday, ... will be webcast at the time of the presentation ...
Breaking Medicine Technology:JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 2JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3
(Date:11/27/2014)... 27, 2014 Allowing children to help with ... school, helps give children responsibility, ownership, boosts self-esteem, and above ... , Now, the real question is, how do you encourage ... According to a study published by Child Development Journal, there ... dramatic effect on a child’s willingness to lend a hand. ...
(Date:11/27/2014)... "The uglier, the better," says Dr. Kirk Kimmerling. "Every ... as we enjoy the ugly sweater contest." Last year's ... " It was a sight to see. She glued ... the Christmas balls were faces of the staff with Dr. ... this year, it's simple to get in on the fun. ...
(Date:11/27/2014)... New Delhi, India (PRWEB) November 27, 2014 ... internet marketing company, has announced online reputation management ... after doing a comprehensive study about the world of ... Google, Bing, and Yahoo. , Ethane Web Technologies ... project. Instead, it first analyzes the project to reach ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 Ethane Web Technologies, ... it will provide a 10% Christmas discount on PPC service. ... December. The discount offer will begin on 1 December 2014 ... , About this offer, a PPC professional working at Ethane ... especially for small businesses, as this big discount would make ...
(Date:11/27/2014)... CA, (PRWEB) November 26, 2014 ... browser-based presentation platform, focused on increasing audience engagement ... Britannic Technologies. Lintelus’ software platform includes a multitude ... and presenter in a collaborative, interactive multi-screen environment. ... and the presentation in real time on their ...
Breaking Medicine News(10 mins):Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3Health News:Ethane Web Technologies Announces Online Reputation Management Service 2Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2Health News:Lintelus Showcases its Feature-Rich Presentation Technology Solution at Convergence Summit’s Annual Event in London 2
... Lahore have arrested four doctors engaged in the illegally removing ... were made Friday night after police apprehended three middlemen and ... heavily guarded house in the city, Lahore police chief Aftab ... former patient then raided two private hospitals where the four ...
... services have been paralysed in a Bihar district as hundreds of ... police in rescuing two abducted school students who are close ... about 125 km from the state capital, went on a two-day ... Saurav, 12 and Gaurav, 12. Both the boys are student of ...
... case of H5N1 infection known as bird flu in a ... by his surname, Cheng, and said he was under treatment ... it did not specify his unit or say which region ... affairs. ,Cheng developed symptoms of fever, coughing and ...
... identify the places most at risk of devastating earthquakes. ... zones' that can spawn giant quakes, researchers attending a ... Society and several Latin American geophysical associations, claimed that ... a locked zone to the west of Seattle. ...
... Center (BMC) and Boston University School of Public Health ... immunodeficiency virus (HIV), who also have alcohol problems, ... virus (HCV). These findings appear in the June issue ... HIV and HCV is a significant medical and public ...
... cancer is an elevated rate of increase in prostate specific ... study found that a pre-treatment rate of PSA increase, called ... with a high risk of death from prostate cancer. Elevated ... other single high-risk indicator, such as a biopsy Gleason score ...
Cached Medicine News:Health News:Persons With HIV and Alcohol Problems Co-infected With Hepatitis C 2Health News:High Pretreatment PSA Velocity Predicts Worse Outcome 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: